The FDA has granted fast track designation to the SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in patients with head and neck cancer.
SGX942 is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability and simultaneous anti-inflammatory and anti-infective activity. The agent has demonstrated safety in a phase I clinical study and efficacy in animal disease models. ■
